XM does not provide services to residents of the United States of America.

Cerebras likely to postpone IPO due to CFIUS review delay on G42 deal, sources say



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>EXCLUSIVE-Cerebras likely to postpone IPO due to CFIUS review delay on G42 deal, sources say</title></head><body>

Cerebras likely to postpone IPO due to CFIUS review delay

CFIUS reviewing G42's investment in Cerebras

G42 business accounted for 83% of Cerebras' 2023 revenue

Cerebras and G42 amended filing to specify non-voting securities

Adds more background on Cerebras

By Echo Wang, Max A. Cherney and Krystal Hu

NEW YORK, Oct 8 (Reuters) -Cerebras Systems is likely to postpone its IPO, after facing delays with a U.S. national security review on UAE-based tech conglomerate G42's minority investment in the AI chipmaker, people familiar with the matter said on Tuesday.

Cerebras, which competes with industry leader Nvidia NVDA.O in the lucrative artificial intelligence chip market, is likely to call off the roadshow that was scheduled for early next week for its highly anticipated initial public offering, the sources said, requesting anonymity as the discussions are confidential.

Cerebras declined to comment. G42 did not respond to requests for comment.

The Committee on Foreign Investment in the United States (CFIUS), which reviews foreign investments over possible national security concerns, is currently looking into G42's investment in Cerebras, the company disclosed in a recent regulatory filing.

Cerebras still expects CFIUS to green-light the G42 deal this year, the sources said. The company will look to proceed with a stock market launch as soon as it receives the necessary clearance from CFIUS, the sources said, cautioning that the plans could change depending on the timing of the approval.

A spokesperson for the U.S. Treasury, which is in charge of CFIUS, declined to comment on the Cerebras IPO, saying that the agency is "committed to taking all necessary actions within its authority to safeguard U.S. national security."

UAE-based technology group G42, which is an investor and the biggest client of Cerebras, has drawn increased scrutiny from China hawks in Washington, amid fears that the UAE and other Middle Eastern companies are becoming a conduit for China to receive advanced American AI technology it is blocked from getting directly from the United States.

Business from G42 accounted for $65.1 million, or 83%, of the total revenue for Cerebras during the year ended December 31, 2023, according to the filing. For the six months ended June 30, Cerebras reported total revenue of $136.4 million, compared to $8.7 million a year earlier.

G42 has committed to buy $335 million worth of Cerebras' stock by April, a deal that would give it a stake of more than 5% in the company.

REVIEW DELAYS

Cerebras and G42 have submitted a joint filing to notify CFIUS of the investment. The companies later amended the filing, specifying that the shares to be acquired by G42 will be non-voting securities, which they argued should not require a CFIUS review.

In September, the companies submitted a request to CFIUS to withdraw the notice. CFIUS is considering the withdrawal request, according to Cerebras' IPO filing.

Sunnyvale, California-based Cerebras, which was valued at about $4 billion in a funding round in 2021, is in the process of building a series of AI data centers for G42. The technology developed by Cerebras has been used to train an Arabic large language model, which is now being served on the Microsoft Azure AI platform.

The processors developed by Cerebras compete directly with the chips made by Nvidia for building large artificial intelligence models and running AI applications. The chip startup is one of the few in Silicon Valley that is adopting a different technical strategy than Nvidia to tackle the same computing challenge faced by customers.

Cerebras CEO Andrew Feldman has previously claimed that the large chip produced by Cerebras carries several technical advantages for AI applications, compared to chips produced by Nvidia and other competitors.

Cerebras tapped Citigroup and Barclays as the lead underwriters for the planned offering.



Reporting by Echo Wang in New York, Max Cherney and Krystal Hu in San Francisco; additional reporting by Alexandra Alper; Editing by Anirban Sen and Nick Zieminski

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.